Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells.

Lin X, Shen J, Dan Peng, He X, Xu C, Chen X, Tanyi JL, Montone K, Fan Y, Huang Q, Zhang L, Zhong X.

Signal Transduct Target Ther. 2018 Aug 31;3:23. doi: 10.1038/s41392-018-0026-5. eCollection 2018.

2.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
3.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

4.

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A.

JCI Insight. 2018 Feb 22;3(4). pii: 94952. doi: 10.1172/jci.insight.94952. [Epub ahead of print]

5.

Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.

Katsnelson M, Hwang WT, Tahirovic E, Rubin SC, Tanyi JL.

J Obstet Gynaecol. 2018 Apr;38(3):395-401. doi: 10.1080/01443615.2017.1336613. Epub 2018 Jan 31.

PMID:
29385863
6.

Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.

O'Hara MH, Stashwick C, Plesa G, Tanyi JL.

Immunotherapy. 2017 Aug;9(9):767-780. doi: 10.2217/imt-2017-0026. Epub 2017 Aug 3. Review.

PMID:
28771103
7.

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.

Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.

Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.

8.

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.

J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.

PMID:
28234665
9.

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.

10.

Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.

Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, Zhang L.

Mol Cell Biol. 2016 Oct 13;36(21):2742-2754. doi: 10.1128/MCB.00079-16. Print 2016 Nov 1.

11.

Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.

Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr.

Gynecol Oncol. 2016 Oct;143(1):120-127. doi: 10.1016/j.ygyno.2016.07.105. Epub 2016 Jul 25.

PMID:
27470997
12.

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL.

Oncotarget. 2016 Jul 26;7(30):48577-48585. doi: 10.18632/oncotarget.9373.

13.

Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer.

Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.

Nat Struct Mol Biol. 2016 Jun;23(6):522-30. doi: 10.1038/nsmb.3211. Epub 2016 Apr 25.

14.

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

O'Hara M, Stashwick C, Haas AR, Tanyi JL.

Immunotherapy. 2016;8(4):449-60. doi: 10.2217/imt.16.4. Review.

15.

Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L.

Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.

16.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, Tanyi JL, Galanis A, Kakolyris S, Trypsianis G, Coukos G, Sandaltzopoulos R.

Biomed Res Int. 2015;2015:712438. doi: 10.1155/2015/712438. Epub 2015 Sep 13.

17.

A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma.

Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Morgan MA, Uribe-Herranz M, Tanyi JL, Facciabene A.

J Immunol. 2015 Oct 15;195(8):4020-7. doi: 10.4049/jimmunol.1500281. Epub 2015 Sep 16.

18.

A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.

Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L.

Cancer Cell. 2014 Sep 8;26(3):344-357. doi: 10.1016/j.ccr.2014.07.009.

19.

MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations.

Tanyi M, Olasz J, Tanyi JL, Tóth L, Antal-Szalmás P, Ress Z, Bubán T, Palatka K, András C, Urbancsek H, Garami Z, Csuka O, Damjanovich L.

Eur J Surg Oncol. 2014 Nov;40(11):1445-52. doi: 10.1016/j.ejso.2014.07.032. Epub 2014 Jul 24.

PMID:
25107687
20.

Predicting time to ovarian carcinoma recurrence using protein markers.

Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG.

J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. Erratum in: J Clin Invest. 2013 Dec 2;123(12):5410.

21.

Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.

Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW.

J Proteomics. 2013 Aug 26;89:165-78. doi: 10.1016/j.jprot.2013.06.016. Epub 2013 Jun 21.

22.

Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.

Beer LA, Wang H, Tang HY, Cao Z, Chang-Wong T, Tanyi JL, Zhang R, Liu Q, Speicher DW.

PLoS One. 2013;8(3):e60129. doi: 10.1371/journal.pone.0060129. Epub 2013 Mar 27.

23.

The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer.

Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, Huang Q, Zhang L.

Mol Cancer Res. 2013 Mar;11(3):240-50. doi: 10.1158/1541-7786.MCR-12-0432. Epub 2013 Jan 21.

24.

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA.

Int J Gynecol Cancer. 2013 Feb;23(2):348-54. doi: 10.1097/IGC.0b013e31827c18f3.

25.

mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells.

Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):617-22. doi: 10.1016/j.bbrc.2012.12.083. Epub 2012 Dec 27.

26.

Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.

Tanyi JL, Chu CS.

Immunotherapy. 2012 Oct;4(10):995-1009. doi: 10.2217/imt.12.100. Review.

PMID:
23148752
27.

Genomic DNA copy-number alterations of the let-7 family in human cancers.

Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L.

PLoS One. 2012;7(9):e44399. doi: 10.1371/journal.pone.0044399. Epub 2012 Sep 6.

28.

Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.

Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS, Lev-Toaff AS.

Abdom Imaging. 2013 Apr;38(2):265-72. doi: 10.1007/s00261-012-9913-3.

PMID:
22627832
29.

Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer.

Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, Shao Z, Liang S, Wang LP, Hwang WT, Katsaros D, Montone K, Zhao X, Zhang L.

J Biol Chem. 2012 May 18;287(21):17386-97. doi: 10.1074/jbc.M111.321158. Epub 2012 Mar 30.

30.

Q48P mutation in the hMLH1 gene associated with Lynch syndrome in three Hungarian families.

Tanyi M, Olasz J, Tanyi JL, Tóth L, Antal-Szalmás P, Bubán T, András C, Urbancsek H, Garami Z, Csuka O, Damjanovich L.

Fam Cancer. 2012 Sep;11(3):519-24. doi: 10.1007/s10689-012-9515-9.

PMID:
22395473
31.

Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms.

Tanyi JL, Marsh EB, Dalmau J, Chu CS.

Acta Obstet Gynecol Scand. 2012 May;91(5):630-4. doi: 10.1111/j.1600-0412.2011.01365.x. Epub 2012 Mar 5.

32.

Papillary thyroid cancer arising in struma ovarii.

Jean S, Tanyi JL, Montone K, McGrath C, Lage-Alvarez MM, Chu CS.

J Obstet Gynaecol. 2012 Apr;32(3):222-6. doi: 10.3109/01443615.2011.645921. Review.

PMID:
22369392
33.

Oncology biomarkers for gynecologic malignancies.

Tanyi JL, Scholler N.

Front Biosci (Elite Ed). 2012 Jan 1;4:1097-110.

PMID:
22201939
34.

Clinical predictors of bevacizumab-associated gastrointestinal perforation.

Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS.

Gynecol Oncol. 2011 Mar;120(3):464-9. doi: 10.1016/j.ygyno.2010.11.009. Epub 2010 Dec 17.

PMID:
21168199
35.

Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity.

Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC.

Gynecol Oncol. 2011 Jan;120(1):108-12. doi: 10.1016/j.ygyno.2010.09.005.

PMID:
20937524
36.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868
37.

A new mutation in Muir-Torre syndrome associated with familiar transmission of different gastrointestinal adenocarcinomas.

Tanyi M, Olasz J, Lukács G, Tanyi JL, Tóth L, Antal-Szalmás P, Ress Z, Bubán T, András C, Damjanovich L.

Eur J Surg Oncol. 2009 Oct;35(10):1128-30. doi: 10.1016/j.ejso.2009.03.011. Epub 2009 May 6. Review.

PMID:
19423266
38.

Balloon tamponade of hemorrhage after uterine curettage for gestational trophoblastic disease.

Kolomeyevskaya NV, Tanyi JL, Coleman NM, Beasley AD, Miller HJ, Anderson ML.

Obstet Gynecol. 2009 Feb;113(2 Pt 2):557-60. doi: 10.1097/AOG.0b013e318193bff3.

PMID:
19155956
39.

Placenta percreta at 7th week of pregnancy in a woman with previous caesarean section.

Tanyi JL, Coleman NM, Johnston ND, Ayensu-Coker L, Rajkovic A.

J Obstet Gynaecol. 2008 Apr;28(3):338-40. doi: 10.1080/01443610802047828. No abstract available.

PMID:
18569483
40.

Difficulties in recognizing families with Hereditary Non-polyposis Colorectal Carcinoma. Presentation of 4 families with proven mutation.

Tanyi M, Olasz J, Kámory E, Csuka O, Tanyi JL, Ress Z, Damjanovich L.

Eur J Surg Oncol. 2008 Dec;34(12):1322-7. doi: 10.1016/j.ejso.2008.01.006. Epub 2008 Mar 4. Erratum in: Eur J Surg Oncol. 2009 Jun;35(6):673.

PMID:
18289827
41.

Pedigree and genetic analysis of a novel mutation carrier patient suffering from hereditary nonpolyposis colorectal cancer.

Tanyi M, Olasz J, Lukács G, Csuka O, Tóth L, Szentirmay Z, Ress Z, Barta Z, Tanyi JL, Damjanovich L.

World J Gastroenterol. 2006 Feb 28;12(8):1192-7.

42.

Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.

Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45.

43.

The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB.

Cancer Res. 2003 Mar 1;63(5):1073-82.

44.

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB.

Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. Review.

PMID:
12069836
45.

Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.

Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J.

Gynecol Oncol. 2002 Jun;85(3):451-8.

PMID:
12051873

Supplemental Content

Loading ...
Support Center